Hi, Brian Lairer here.

Up next, Brian Lairor Weekend,

three of our favorite segments from the week,

packaged together for you to listen to on the weekend.

So enjoy, and I'll see you back on the radio Monday at 10 a.m.

on WNYC on WNYC.

Good morning again, everyone.

Now we'll revisit a rapidly evolving topic that continues to get so much attention culturally, medically, and financially. The technical term is

GLP1 agonist medications, but they're more commonly known by the brand names, Oempec, Ragovi, or Manjaro,

or by the active ingredients, semi-glutide, a class of medication created to treat diabetes.

But they carry a socially desirable side effect, easy weight loss.

These drugs are seemingly everywhere, as I don't have to tell you, yet incredibly elusive in a certain way.

Maybe you've seen them advertised in subway cars, in speculative conversations about celebrities,

or you've personally discussed the pros and cons of using these drugs with your doctor,

or use them yourselves on-label or off.

Perhaps you've come across headlines describing

revolutionary impacts like can weight loss drugs such as OSemphic also treat addiction and dementia

from the Guardian? We talked about that one. Or will the OZempic era change how we think about being

fat and being thin from the New Yorker.

We had the writer of that article on.

There's a New York Times story just today about their potential for treating kidney disease.

But while the discussion is endless, the supply is not.

...